跳至主要内容
临床试验/NCT00882427
NCT00882427已完成不适用

Single-center, Open Study on the Performance of the Software eMPC Algorithm Used for Blood Glucose Control Over an Extended Glucose Control Range (4.4 to 8.3 mmol/L) for a Maximum of 48 Hours in Postoperative Cardiac Surgery Patients in the Intensive Care Unit

B. Braun Melsungen AG1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2009年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
1
主要终点
percentage of time within the predefined glucose target range of 80-150 mg/dL

研究概览

简要总结

Hyperglycaemia is commonly found in critically ill patients. Clinical studies demonstrated that tight blood glucose control in medical and surgical ICU patients results in a significant better outcome for the patients. Based on this emerging clinical evidence, there are increasing efforts worldwide to maintain strict glycaemic control in critically ill patients. However, achieving this goal requires extensive nursing efforts, including frequent bedside glucose monitoring and the implementation of complex intensive insulin infusion protocols. A fully automated algorithm may help to overcome some of these limitations by excluding intuitive interventions and integrating relevant clinical data in the decision-making process. This study will investigate the performance of an eMPC algorithm adjusted to target the range 4.4 - 8.3 mmol/L in line with the Surviving Sepsis guidelines.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: > 18 years of age
  • Admitted following cardiac surgery
  • Stay in the ICU expected to be > 20h
  • Blood glucose > 6.7 mmol/l within 4 hours of admission to intensive care or patient already receiving insulin treatment

排除标准

  • Patients with hyperglycaemic crisis/ketoacidosis due to insulin deficiency.
  • Known or suspected allergy to insulin
  • Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient (i.e. liver failure, other fatal organ failures)
  • Patients participating in another study
  • Moribund patients likely to die within 24 hours
  • Patients after organ transplantation within the last three months
  • Patients under high dose cortisol treatment (cortisol > 1000 mg/day or equivalent doses of hydrocortisol)

结局指标

主要结局

percentage of time within the predefined glucose target range of 80-150 mg/dL

时间窗: from start of treatment to the last glucose measurement under treatment

次要结局

  • Hypoglycemias(from start of treatment to the last glucose measurement under treatment)
  • Usability parameters like convenience of alarming function; workload; blood sampling frequency(from start of treatment to the last glucose measurement under treatment)
  • Concomitant medication including insulin infusion rate, parenteral/enteral nutrition(from start of treatment to the last glucose measurement under treatment)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验